stockrowEquillium, Inc.
Equillium, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $41.1 million, up 13.9% from fiscal 2023.
- Revenue
- −52.3%
- EPS
- +75.0%
- Free cash flow
- −38.7%
Quarter to June 2026, against a year earlier
Follow EQ
Alert me
Equillium, Inc. (EQ) EV/Sales
As of 5 November 2026, Equillium, Inc. (EQ) trades at a EV/Sales of 2.4×. Over the past ten years it has ranged from −0.5× (November 2023) to 7.5× (June 2026); the current reading is higher than 93% of that period. That is below the Biotechnology industry median of 9.0× and below the Healthcare sector median of 3.5×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2024 | 0.3× | — |
| FY2023 | −0.2× | — |
| FY2022 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Dec 2024 | 0.3× | 15.96% |
| Sep 2024 | 0.2× | — |
| Jun 2024 | 0.0× | — |
| Mar 2024 | 1.3× | — |
| 5 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| TNXP Tonix Pharmaceuticals Holding Corp. compare | −3.2× |
| RLYB Rallybio Corporation compare | −0.9× |
| PLYX Polaryx Therapeutics, Inc. compare | n/m |
| KZIA Novogen Limited compare | n/m |
| CLLS Cellectis S.A. compare | 0.1× |
| VXRT VAXART, INC. compare | 0.1× |
| EQ Equillium, Inc. | 2.4× |
| GNLX Genelux Corporation compare | 6.3× |
| NRXS Neuraxis, Inc. compare | 12.2× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.5× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)